Oak Hill Uses a $175M SPAC to Revive Roche’s Angelman Drug
Oak Hill Bio plans to reach Nasdaq through a SPAC transaction that could provide $175 million to develop a former Roche programme for Angelman syndrome.
A drug programme left behind by a large pharmaceutical company is getting a second route to the public market.
What happened
Oak Hill Bio agreed to merge with Research Alliance Corporation III, a SPAC sponsored by RA Capital.
The proposed transaction would provide $175 million: $75 million from the SPAC’s trust and $100 million from private financing. Oak Hill is developing rugonersen, a former Roche programme for Angelman syndrome.
The company plans to use the capital to support Phase 3 development and a possible regulatory submission in 2029. The merger is expected to close by year-end but is not yet complete.
Why it matters
Large pharmaceutical companies regularly discontinue programmes for strategic, financial or clinical reasons. Specialist investors can sometimes acquire those assets and build focused companies around them.
The structure gives Oak Hill access to public-market capital without a conventional IPO. It also places substantial execution risk on one clinical programme aimed at a rare neurological condition.
The bigger picture
SPACs are no longer receiving the excitement they attracted earlier in the decade, but they can still be useful financing vehicles for specialist biotechnology deals.
This transaction is also a test of the drug-revival model: whether a smaller company with dedicated capital can create value from a programme a larger owner chose not to prioritise.